Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)

NIH to study Pfiz­er's Paxlovid in long Covid as de­mand — and in­fec­tions — con­tin­ue to fall

Pfiz­er’s Paxlovid will be­come the first treat­ment stud­ied by the NIH for long Covid, the agency said Thurs­day.

The drug will be eval­u­at­ed as part of the NIH’s $1 bil­lion RE­COV­ER pro­gram, with re­searchers try­ing to fig­ure out the cause of the con­di­tion and a way to treat it. Cur­rent­ly, there are more than 200 symp­toms as­so­ci­at­ed with long Covid, in­clud­ing fa­tigue, pain, brain fog and ir­reg­u­lar heart­beat, all of which can per­sist for months or years af­ter Covid-19.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA